Home | Welcome to Contract Pharma   
Last Updated Friday, August 1 2014
Print

Andromeda Acquires Teva’s DiaPep277 Rights



By Kristin Brooks



Published February 24, 2014
Related Searches: Phase III Development
Andromeda Biotech Ltd. has entered an agreement with Teva Pharmaceutical Industries Ltd. to acquire Teva's rights for Andromeda's drug DiaPep277 for the treatment of type 1 diabetes. Teva will transfer its DiaPep277 rights and all of its shares in Andromeda, for total of approximately $72 million, payable in installments through future payments based on Andromeda's revenues or on proceeds payable to its shareholders.
 
Andromeda will work to ensure that the current Phase III development program of DiaPep277 will continue according to plan, without delays in an effort to gain regulatory approval.
 
 
 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On